1. A product containing macitentan or a pharmaceutically acceptable salt of this compound in combination with at least one compound having agonistic properties for the prostacyclin receptor (IP), or a pharmaceutically acceptable salt thereof. ! 2. The product according to claim 1, in which the compound having agonistic properties against the prostacyclin receptor (IP) is selected from treprostinil and its pharmaceutically acceptable salts, epoprostenol and its pharmaceutically acceptable salts, iloprost and its pharmaceutically acceptable salts, beraprost and its pharmaceutically acceptable salts, 2- {4 - [(5,6-diphenylpyrazin-2-yl) (isopropyl) amino] butoxy} -N- (methylsulfonyl) acetamide and its pharmaceutically acceptable salts and {4 - [(5,6-diphenylpyrazine -2-yl) (isopropyl) amino] butoxy} -acetic acid and its pharmaceutical vticheski acceptable salts. ! 3. The product according to claim 2, in which the compound having agonistic properties against the prostacyclin receptor (IP) is selected from 2- {4 - [(5,6-diphenylpyrazin-2-yl) (isopropyl) amino] butoxy} - N- (methylsulfonyl) acetamide and its pharmaceutically acceptable salts and {4 - [(5,6-diphenylpyrazin-2-yl) (isopropyl) amino] butoxy} acetic acid and its pharmaceutically acceptable salts. ! 4. The product according to claim 3, in which the compound having agonistic properties against the prostacyclin receptor (IP) is 2- {4 - [(5,6-diphenylpyrazin-2-yl) (isopropyl) amino] butoxy} -N - (methylsulfonyl) acetamide or a pharmaceutically acceptable salt thereof. ! 5. A product containing macitentan or a pharmaceutically acceptable salt of this compound in combination with at least one compound having agonistic properties1. Продукт, содержащий мацитентан или фармацевтически приемлемую соль данного соединения в сочетании по крайней мере с одним соединением, обладающим агонистическими свойствами в отношении простациклинового рецептора (IP), или его фармацевтически приемлемой солью. ! 2. Продукт по п.1, в которо
